Journal of International Oncology ›› 2024, Vol. 51 ›› Issue (6): 350-353.doi: 10.3760/cma.j.cn371439-20240218-00060
• Reviews • Previous Articles Next Articles
Received:
2024-02-18
Revised:
2024-03-10
Online:
2024-06-08
Published:
2024-06-28
Contact:
Zhang Junwang, Email: Supported by:
Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[1] |
Vainberg IE, Lewis SA, Rommelaere H, et al. Prefoldin, a chape-rone that delivers unfolded proteins to cytosolic chaperonin[J]. Cell, 1998, 93(5): 863-873. DOI: 10.1016/s0092-8674(00)81446-4.
pmid: 9630229 |
[2] |
Gestaut D, Roh SH, Ma BX, et al. The chaperonin TRiC/CCT associates with prefoldin through a conserved electrostatic interface essential for cellular proteostasis[J]. Cell, 2019, 177(3): 751-765.e15. DOI: 10.1016/j.cell.2019.03.012.
pmid: 30955883 |
[3] | Tahmaz I, Shahmoradi Ghahe S, Topf U. Prefoldin function in cellular protein homeostasis and human diseases[J]. Front Cell Dev Biol, 2021, 9: 816214. DOI: 10.3389/fcell.2021.816214. |
[4] |
Wang P, Zhao J, Yang X, et al. PFDN1, an indicator for colorectal cancer prognosis, enhances tumor cell proliferation and motility through cytoskeletal reorganization[J]. Med Oncol, 2015, 32(12): 264. DOI: 10.1007/s12032-015-0710-z.
pmid: 26553318 |
[5] |
Miyazawa M, Tashiro E, Kitaura H, et al. Prefoldin subunits are protected from ubiquitin-proteasome system-mediated degradation by forming complex with other constituent subunits[J]. J Biol Chem, 2011, 286(22): 19191-19203. DOI: 10.1074/jbc.M110.216259.
pmid: 21478150 |
[6] | Peñate X, Praena-Fernández JM, Romero Pareja P, et al. Over-expression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer[J]. Cancers (Basel), 2020, 12(4): 1052. DOI: 10.3390/cancers12041052. |
[7] | Zhao HC, Chen CZ, Yang CL, et al. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy[J]. Pathol Res Pract, 2022, 232: 153808. DOI: 10.1016/j.prp.2022.153808. |
[8] | Jiang LL, Liu J. Prefoldin 6 promotes glioma progression via the AKT signalling pathway[J]. Cell Biol Int, 2023, 47(1): 52-62. DOI: 10.1002/cbin.11895. |
[9] |
Yang KY, Wu ZJ, Zhang H, et al. Glioma targeted therapy: insight into future of molecular approaches[J]. Mol Cancer, 2022, 21(1): 39. DOI: 10.1186/s12943-022-01513-z.
pmid: 35135556 |
[10] | Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012—2016[J]. Neuro Oncol, 2019, 21(Suppl 5): v1-v100. DOI: 10.1093/neuonc/noz150. |
[11] | Cai JY, Hu YY, Ye Z, et al. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour micro-environment in lower-grade glioma[J]. Front Immunol, 2022, 13: 1011757. DOI: 10.3389/fimmu.2022.1011757. |
[12] | Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(6): 524-541. DOI: 10.3322/caac.21754. |
[13] |
Sarhangi N, Hajjari S, Heydari SF, et al. Breast cancer in the era of precision medicine[J]. Mol Biol Rep, 2022, 49(10): 10023-10037. DOI: 10.1007/s11033-022-07571-2.
pmid: 35733061 |
[14] | Hashemi M, Arani HZ, Orouei S, et al. EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions[J]. Biomed Pharmacother, 2022, 155: 113774. DOI: 10.1016/j.biopha.2022.113774. |
[15] | 黄超有, 李玺, 韩铮, 等. Prefoldin 1对乳腺癌BT474细胞上皮-间充质转化的影响[J]. 实用医学杂志, 2019, 35(1): 47-50. DOI: 10.3969/j.issn.1006-5725.2019.01.010. |
[16] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. |
[17] | Li YT, Yan BS, He SM. Advances and challenges in the treatment of lung cancer[J]. Biomed Pharmacother, 2023, 169: 115891. DOI: 10.1016/j.biopha.2023.115891. |
[18] |
Wang D, Shi W, Tang Y, et al. Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression[J]. Oncogene, 2017, 36(7): 885-898. DOI: 10.1038/onc.2016.257.
pmid: 27694898 |
[19] | Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives[J]. J Hematol Oncol, 2023, 16(1): 57. DOI: 10.1186/s13045-023-01451-3. |
[20] | 于晓鹏, 冯青青, 赵文飞, 等. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635. DOI: 10.3760/cma.j.cn371439-20230428-00120. |
[21] | Zhou C, Guo ZY, Xu LQ, et al. PFND1 predicts poor prognosis of gastric cancer and promotes cell metastasis by activating the Wnt/β-catenin pathway[J]. Onco Targets Ther, 2020, 13: 3177-3186. DOI: 10.2147/OTT.S236929. |
[22] |
Malagoli Tagliazucchi G, Wiecek AJ, Withnell E, et al. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer[J]. Nat Commun, 2023, 14(1): 789. DOI: 10.1038/s41467-023-36439-7.
pmid: 36774358 |
[23] | Chen TN, He QM, Xiang ZX, et al. Identification and validation of key genes of differential correlations in gastric cancer[J]. Front Cell Dev Biol, 2021, 9: 801687. DOI: 10.3389/fcell.2021.801687. |
[24] | He QM, Ding ZY, Chen TN, et al. PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer[J]. Front Oncol, 2023, 13: 1164070. DOI: 10.3389/fonc.2023.1164070. |
[25] | Shao YF, Yesseyeva G, Zhi YH, et al. Comprehensive multi-omics analysis and experimental verification reveal PFDN5 is a novel prognostic and therapeutic biomarker for gastric cancer[J]. Genomics, 2024, 116(2): 110821. DOI: 10.1016/j.ygeno.2024.110821. |
[26] | Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(1): 188314. DOI: 10.1016/j.bbcan.2019.188314. |
[27] | Ke SJ, Lu SN, Wang CQ, et al. Comprehensive analysis of the prognostic value and functions of prefoldins in hepatocellular carcinoma[J]. Front Mol Biosci, 2022, 9: 957001. DOI: 10.3389/fmolb.2022.957001. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[6] | Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[7] | Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[8] | Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[9] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[10] | Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[11] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[12] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[13] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[14] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297. |
[15] | Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||